Last reviewed · How we verify
DS-8273A
At a glance
| Generic name | DS-8273A |
|---|---|
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma (PHASE1)
- Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer (PHASE1)
- Open-label Study of DS-8273a to Assess Its Safety and Tolerability, and Assess Its Pharmacokinetic and Pharmacodynamic Properties in Subjects With Advanced Solid Tumors or Lymphomas (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DS-8273A CI brief — competitive landscape report
- DS-8273A updates RSS · CI watch RSS